Search - tctmd.com

Displaying 161 - 180 of 217

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

Presentation JIM 2017

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Presenter: Dominick J. Angiolillo

February 10, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

Michael O'Riordan

December 13, 2016

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

News Daily News

Use of Evidence-Based Medical Therapy Steadily Improving in Acute MI Patients Postdischarge

Michael O'Riordan

September 30, 2016

Presentation ACC 2016

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Presenter: Dominick Angiolillo

April 03, 2016

News Daily News

Calculator Estimates Spontaneous MI Risk in Medically Managed NSTE ACS Patients

Todd Neale

March 16, 2016

Presentation JIM 2016

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Presenter: Alberto Menozzi

February 11, 2016

Presentation JIM 2016

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Presenter: Roxana Mehran

February 11, 2016

News Daily News

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

L.A. McKeown

February 09, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Daily News

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Caitlin E. Cox

December 20, 2015

News Daily News

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Todd Neale

December 14, 2015

News Daily News

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Shelley Wood

October 29, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for May 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Use of Evidence-Based Medical Therapy Steadily Improving in Acute MI Patients Postdischarge

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Calculator Estimates Spontaneous MI Risk in Medically Managed NSTE ACS Patients

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content